|Podcasts|February 14, 2019
Episode 25: China’s Pharma Growth
Author(s)Michelle Maskaly, Christen Harm
Michelle Maskaly and Christen Harm talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China’s exploding pharma and biotech industries, as well as the country’s push to become a global life science leader.
Advertisement
Michelle Maskaly and Christen Harm talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China’s exploding pharma and biotech industries, as well as the country’s push to become a global life science leader.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why Do a Significant Number of GLP-1 Users Stop Taking the Medication in the First Year?
2
Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics
3
The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation
4
Bringing the Bayesian Method to Clinical Trials: Q&A with Dr. Stacy Lindborg
5